Literature DB >> 28449468

Pulmonary inflammatory myofibroblastic tumor versus IgG4-related inflammatory pseudotumor: differential diagnosis based on a case series.

Longfei Zhu1, Jian Li1, Chengwu Liu1, Wenshuang Ding2, Feng Lin1, Chenglin Guo1, Lunxu Liu1.   

Abstract

BACKGROUND: Pulmonary inflammatory myofibroblastic tumor (IMT) has been considered as a synonym for inflammatory pseudotumor (IPT) for a long time. Recent studies have indicated that IMT and IgG4-related IPT are distinct diseases. However, no consensus criteria have been recommended. Here we propose a set of criteria for the differential diagnosis.
METHODS: Twenty-six archived IMT and IgG4-related IPT samples were examined for histological characteristics and the expression of IgG, IgG4, SMA and ALK-1. Based on our proposed criteria, we reclassified the cases into either IMT or IgG4-related IPT group and compared the clinicopathological features, laboratory findings, overall survivals (OS) and disease-free survivals between groups to validate the effectiveness and dependability of the diagnostic criteria.
RESULTS: The average age of IgG4-related IPT group was higher than IMTs (48.82 vs. 39.22 years, P=0.031). In IMT group, tumors were characterized by bigger tumor sizes (3.47 vs. 2.22 cm, P=0.007), diffuse and total destroyed alveoli (88.89% vs. 17.65%, P=0.002), fewer lymphoid follicles (1.6/HPF vs. 3.0/HPF, P=0.045) and lower expression of IgG (74.7/HPF vs. 149.1/HPF; P<0.001). As an exclusion criterion of IgG4-related IPT, ALK-positivity was correlated with the higher cytological atypia (mean 3.7/HPF, P<0.001) and lesser lymphoid follicles (mean 1.2/HPF, P=0.021). And it's the first study to show the liner positive correlation between the lymphocytes + plasma cells count and IgG4-positive plasma cells count in these lesions (r=0.914, P<0.001). The negative correlation between the IgG4-positive plasma cells count and the expression of ALK-1 are reported for the first time as well (rs=-0.632, P=0.001). However, despite two patients with recurrence or metastasis were divided into IMT group, only borderline values were detected in the survival analysis (OS 88.89% vs. 100%, P=0.197, DFS 77.78% vs. 100.00%; P=0.056).
CONCLUSIONS: The significant differences of clinicopathological characteristics between the IMTs and IgG4-related IPTs indicated that a combination of lymphocytes + plasma cells count, cytological atypia, IgG4 and ALK-1 staining will be helpful in differential diagnosis.

Entities:  

Keywords:  Inflammatory myofibroblastic tumor (IMT); differential diagnosis; inflammatory pseudotumor (IPT)

Year:  2017        PMID: 28449468      PMCID: PMC5394068          DOI: 10.21037/jtd.2017.02.89

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  20 in total

1.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

Authors:  B Lawrence; A Perez-Atayde; M K Hibbard; B P Rubin; P Dal Cin; J L Pinkus; G S Pinkus; S Xiao; E S Yi; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.

Authors:  C A Griffin; A L Hawkins; C Dvorak; C Henkle; T Ellingham; E J Perlman
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

3.  IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link?

Authors:  Shahrazadb T Saab; Jason L Hornick; Christopher D Fletcher; Sandra J Olson; Cheryl M Coffin
Journal:  Mod Pathol       Date:  2011-02-04       Impact factor: 7.842

Review 4.  Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease.

Authors:  Terumi Kamisawa; Atsutake Okamoto
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

5.  Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study.

Authors:  Hidetaka Yamamoto; Hiroshi Yamaguchi; Shinichi Aishima; Yoshinao Oda; Kenichi Kohashi; Yumi Oshiro; Masazumi Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  2009-09       Impact factor: 6.394

6.  Pulmonary inflammatory myofibroblastic tumor and IgG4-related inflammatory pseudotumor: a diagnostic dilemma.

Authors:  Priyanka Bhagat; Amanjit Bal; Ashim Das; Navneet Singh; Harkant Singh
Journal:  Virchows Arch       Date:  2013-10-08       Impact factor: 4.064

7.  Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.

Authors:  Cheryl M Coffin; Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2007-04       Impact factor: 6.394

Review 8.  Inflammatory myofibroblastic tumours: where are we now?

Authors:  B C Gleason; J L Hornick
Journal:  J Clin Pathol       Date:  2007-10-15       Impact factor: 3.411

9.  Pulmonary inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene.

Authors:  Akihiko Sokai; Makiko Enaka; Risa Sokai; Shoichi Mori; Shunsuke Mori; Masaharu Gunji; Masahiko Fujino; Masafumi Ito
Journal:  Jpn J Clin Oncol       Date:  2013-11-24       Impact factor: 3.019

10.  Complete remission of ALK-negative plasma cell granuloma (inflammatory myofibroblastic tumor) of the lung induced by celecoxib: A case report and review of the literature.

Authors:  Cinderella Chavez; Mark A Hoffman
Journal:  Oncol Lett       Date:  2013-03-15       Impact factor: 2.967

View more
  7 in total

1.  The Clinical and Radiological Characteristics of Inflammatory Myofibroblastic Tumor Occurring at Unusual Sites.

Authors:  Xuewei Zeng; Huayi Huang; Jun Li; Jiayou Peng; Jiaxiong Zhang
Journal:  Biomed Res Int       Date:  2018-05-14       Impact factor: 3.411

2.  Inflammatory myofibroblastic tumours of the thorax: Radiologic and clinicopathological correlation.

Authors:  Aparna Irodi; Binita R Chacko; Anand Prajapati; Anne J Prabhu; Leena R Vimala; Devasahayam J Christopher; Birla R Gnanamuthu
Journal:  Indian J Radiol Imaging       Date:  2020-10-15

3.  Distinct clinicopathological features of pulmonary primary angiomatoid fibrous histiocytoma: A report of four new cases and review of the literature.

Authors:  Zheng Wang; Liping Zhang; Li Ren; Dongge Liu; Jun Du; Min Zhang; Ge Lou; Ying Song; Yin Wang; Chunyan Wu; Guiping Han
Journal:  Thorac Cancer       Date:  2020-12-12       Impact factor: 3.500

4.  Clinical characteristics and outcomes of 17 cases of inflammatory myofibroblastic tumor at a University Hospital in China.

Authors:  Wei Song; Yan Zhu
Journal:  Oncol Lett       Date:  2020-11-18       Impact factor: 2.967

5.  CT Signs and Differential Diagnosis of Peripheral Lung Cancer and Inflammatory Pseudotumor: A Meta-Analysis.

Authors:  Shiyi Zheng; Jie Shu; Jianan Xue; Caiyun Ying
Journal:  J Healthc Eng       Date:  2022-01-03       Impact factor: 2.682

6.  Inflammatory Myofibroblastic Tumor of the Pancreas: A Case Report and Literature Review.

Authors:  Kyungjae Lim; Jinhan Cho; Min Gyoung Pak; Heejin Kwon
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2020-11-30

7.  Aggressive Inflammatory Myofibroblastic Tumor without Anaplastic Lymphoma Kinase Gene Rearrangement in the Rectum with Liver Metastasis.

Authors:  Yosuke Shimodaira; Kae Sugawara; Sho Fukuda; Yusato Suzuki; Noboru Watanabe; Shigeto Koizumi; Reina Ohba; Yuko Hiroshima; Tamotsu Matsuhashi; Hiroshi Nanjo; Katsunori Iijima
Journal:  Intern Med       Date:  2019-10-07       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.